Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies

Abstract Background Chimeric antigen receptor T cell (CAR-T) therapy achieves high remission rates in lymphoid malignancies, but its long-term efficacy is limited by poor persistence and T cell exhaustion. Pomalidomide, an immunomodulatory drug (IMiD), demonstrates clinical synergy with CAR-T therap...

Descrición completa

Detalles Bibliográficos

Principais autores:	Yi Zhou, Yan Yu, Linzhi Xie, Liwen Wang, Yuhan Yan, Qian Cheng, Jing Liu, Chang Zhang, Xin Li
Formato:	Artigo
Idioma:	Inglês
Publicado:	Springer 2025-12-01
Series:	Cancer Immunology, Immunotherapy
Assuntos:	CAR-T therapy Pomalidomide Immune microenvironment Memory T cell Lymphoid malignancies
Acceso en liña:	https://doi.org/10.1007/s00262-025-04247-1
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!